MML Investors Services LLC Purchases New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

MML Investors Services LLC acquired a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 14,497 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,785,000.

Several other large investors also recently made changes to their positions in the business. Dimensional Fund Advisors LP grew its holdings in Jazz Pharmaceuticals by 18.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after acquiring an additional 320,724 shares during the last quarter. Pacer Advisors Inc. lifted its position in shares of Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after purchasing an additional 115,102 shares in the last quarter. Capital World Investors grew its stake in shares of Jazz Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company’s stock valued at $236,860,000 after purchasing an additional 104,195 shares during the last quarter. GW&K Investment Management LLC raised its position in Jazz Pharmaceuticals by 26.6% in the 4th quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock worth $57,142,000 after purchasing an additional 97,589 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Jazz Pharmaceuticals by 501.4% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company’s stock worth $13,800,000 after buying an additional 93,422 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several research reports. Barclays reissued an “overweight” rating and issued a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. HC Wainwright raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a research note on Monday, March 10th. Piper Sandler reissued an “overweight” rating and set a $176.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Royal Bank of Canada reduced their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $187.71.

Jazz Pharmaceuticals Trading Up 3.1 %

NASDAQ JAZZ opened at $116.41 on Wednesday. Jazz Pharmaceuticals plc has a 52 week low of $95.49 and a 52 week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock’s 50 day moving average price is $123.79 and its two-hundred day moving average price is $122.40. The stock has a market capitalization of $7.07 billion, a price-to-earnings ratio of 16.40, a PEG ratio of 1.04 and a beta of 0.42.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $123.75, for a total value of $185,625.00. Following the sale, the chief executive officer now owns 440,307 shares of the company’s stock, valued at approximately $54,487,991.25. The trade was a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 1,140 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $137.81, for a total value of $157,103.40. Following the sale, the chief accounting officer now owns 7,012 shares in the company, valued at $966,323.72. The trade was a 13.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,736 shares of company stock valued at $4,023,305 over the last 90 days. 4.20% of the stock is owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.